Welcome to Cellzome
Cellzome is a privately-owned drug discovery and development company and a leader in the use of chemical proteomics technology. We are using our technology to identify a new generation of drug candidates for the treatment of inflammatory diseases.
Collaboration exploits Cellzome's world-leading proteomics technology in epigenetics
Cambridge, United Kingdom and Heidelberg, Germany, 10th March 2010 - Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response. more ...
Cambridge, United Kingdom and Heidelberg, Germany, 10th March 2010 - Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response. more ...
Heidelberg, Germany, 23rd November 2009 - Cellzome announces that an article published today in Virology has shown that multiple cyclophilins - enzymes that facilitate protein folding - are involved in hepatitis C virus replication. The paper was published by scientists from Cellzome and Novartis Institutes of Biomedical Research (NIBR). In the study, two hepatitis C virus (HCV) drug candidates have been shown to interact with different cyclophilins and thus can attenuate viral replication. Interestingly, the different enzymes are found to participate in different cellular processes, the most prominent one being protein trafficking. more ...
Melbourne, Australia, Cambridge, United Kingdom and Heidelberg, Germany, 8th June 2010 - SYN|thesis Med Chem Pty Ltd. and its affiliate, Qubist Molecular Design, announced today that they have signed an agreement with Cellzome to provide contract medicinal chemistry services. more ...
Integrated chemical genetics and proteomics approach identifies new potential drug targets in Wnt pathway
Heidelberg, Germany, 16th September 2009 - Cellzome announces today, the publication entitled 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling' is now available online in Nature. The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. more ...
Heidelberg, Germany, 16th September 2009 - Cellzome announces today, the publication entitled 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling' is now available online in Nature. The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. more ...
| Date | Conference | Location |
|---|---|---|
| 21-23 Jun 2010 | Micromethods in protein analysis | Martinsried, Munich |
| 10-13 Jul 2010 | 18th Annual Intelligent Systems for Molecular Biology | Boston |
| 19-21 Jul 2010 | Europython 2010 | Birmingham, UK |
| 22-25 Sep 2010 | EMBL Chemical Biology Meeting | Heidelberg |
| 26-28 Sep 2010 | IMPRS - Chemical Biology: Exploring the Interface | Dortmund |
| 10-12 Oct 2010 | 18th Annual BioPartnering Europe | London |
| 23-27 Oct 2010 | 4th EUPA meeting | Estoril, Portugal |
| 02-04 Nov 2010 | CHI's 8th International Discovery on Target | Boston |
| 15-17 Nov 2010 | 16th Annual Bio-Europe | Munich |